Dr Alan Shaw, President and CEO, Codexis (left) and S Iswaran, Minister of State for Trade and Industry (right) jointly commemorate the official opening of Codexis Laboratories Singapore Pte. Ltd.
|
| |
Codexis, Inc., one of the top biocatalysts companies and a leading developer of clean manufacturing processes, is investing more than S$70 million (US$48.3 million) to set up its research facility in Singapore.
The company engineers biocatalysts that make the production of pharmaceuticals, biofuels and industrial products faster, cleaner and less expensive. Among Codexis' customers are industry leaders like Pfizer, Merck and Shell.
Codexis Laboratories Singapore Pte. Ltd., the company's first research facility in Asia, will support its pharmaceuticals business in both the innovator and generics markets. The 20,000-sq ft facility, located in Science Park III, is expected to house up to 70 R&D and operations personnel when fully operational.
"Our expansion to Singapore is a significant part of our global development strategy," says Dr Alan Shaw, President and CEO, Codexis. "Singapore offers us access to a highly skilled workforce, proximity to our growing customer base, and a productive business environment as our company grows. Codexis Laboratories Singapore will play an important role in the development of new products serving our pharmaceuticals markets worldwide."
|
|
|
